Pembrolizumab KEYNOTE-001: An adaptive study leading to accelerated approval for two indications and a companion diagnostic

Annals of Oncology

Volumn 28, Issue 6, 2017, Pages 1388-1398

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADVANCED CANCER; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG BINDING SITE; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; MELANOMA; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING; ANTAGONISTS AND INHIBITORS; LUNG TUMOR;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85021068496     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx076     Document Type: Article

References (78)

1. Wu HC, Chang DK, Huang CT. Targeted therapy for cancer. J Cancer Mol 2006; 2: 57-66.
2. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008; 77: 311-319.
3. Miller MJ, Foy KC, Kaumaya PT. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med 2013; 15: 166-176.
4. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 2013; 8: 277-302.
5. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012; 12: 621-628.
6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
8. Cavallo F, De GC, Nanni P, et al. The immune hallmarks of cancer. Cancer Immunol Immunother 2011; 60: 319-326.
9. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736.
10. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21: 1712-1717.
11. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15: 5591-5598.
12. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
13. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med 2013; 2: 662-673.
14. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-548.
15. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
16. Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8: 765-772.
17. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. AmJ Clin Oncol 2016; 39: 98-106.
18. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219-242.
19. He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep 2015; 5: 13110.
20. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24: 207-212.
21. Yearley J, Gibson G, Yu N, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Eur J Biochem FEBS 2016; 51(suppl 3): S718.
22. Keytruda [package insert]. Whitehouse Station, NJ, Merck Sharp & Dohme Corp.; 2015.
23. US Food and Drug Administration. FDA approves Keytruda for advanced melanoma [press release]. 2014. http://www.fiercebiotech.com/biotech/fda-approves-keytruda-for-advanced-melanoma (28 February 2017, date last accessed).
24. US Food and Drug Administration. US Department of Health and Human Services. FDA orphan drug designations and approvals. Pembrolizumab. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm? cfgridkey=381012 (28 February 2017, date last accessed).
25. Merck announces breakthrough therapy designation for lambrolizumab an investigational antibody therapy for advancedmelanoma [press release].4-24-2013. http://www.mercknewsroom.com/press-release/research-anddevelopment- news/merck-announces-breakthrough-therapy-designationlambrol (28 February 2017, date last accessed).
26. US Food and Drug Administration. Guidance for industry. Expedited programs for serious conditions-drugs and biologics. May 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinforma tion/guidances/ucm358301.pdf (28 February 2017, date last accessed).
27. Keytruda [summary of product characteristics]. Belgium: Schering- Plough Lab NV; 2015.
28. Merck receives FDA breakthrough therapy designation for Keytruda (pembrolizumab) in advanced non-small cell lung cancer [press release]. 10-27-2014. http://www.mercknewsroom.com/news-release/oncologynewsroom/merck-receives-fda-breakthrough-therapy-designation-key truda-pembroli (28 February 2017, date last accessed).
29. FDA approves Keytruda (pembrolizumab) for the treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 with disease progression on or after platinum-containing chemotherapy [press release]. 10-2-2015. http://www.mercknewsroom.com/news-re lease/prescription-medicine-news/fda-approves-keytruda-pembrolizu mab-treatment-patients-metas (28 February 2017, date last accessed).
30. US Food and Drug Administration. Premarket approval (PMA) PD-L1 IHC 22C3 pharmDX. 2016. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?id=P150013 (28 February 2017, date last accessed).
31. Dako. Dako, an Agilent Technologies company, announces FDA approval of new companion diagnostic for lung cancer [press release]. http://www.agilent.com/about/newsroom/presrel/2015/02oct-dk 15004.html (28 February 2017, date last accessed).
32. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-534.
33. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl JMed 2010; 363: 733-742.
34. Mu CY, Huang JA, Chen Y, et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011; 28: 682-688.
35. Sun JM, Zhou W, Choi SJ, et al. PD-L1 expression and survival in patients with non-small cell lung cancer (NSCLC) in Korea. J Clin Oncol 2014; 32(suppl 5): Abstr 8066.
36. Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009; 15: 971-979.
37. Wu P, Wu D, Li L, et al. PD-L1 and survival in solid tumors: a meta-analysis. PLoS ONE 2015; 10: e0131403.
38. Deeks ED. Pembrolizumab: a review in advanced melanoma. Drugs 2016; 76: 375-386.
39. McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today 2015; 51: 7-20.
40. Khoja L, Butler MO, Kang SP, et al. Pembrolizumab. J Immunother Cancer 2015; 3: 36.
41. Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 2015; 21: 4286-4293.
42. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
43. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor- treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-1117.
44. Hamid O, Robert C, Ribas A, et al. Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumabrefractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL). J Clin Oncol 2014; 32(suppl 15): Abstr 3000.
45. Robert C, Joshua AM, Weber JS, et al. Pembrolizumab (pembro; MK- 3475) for advanced melanoma (MEL): randomized comparison of two dosing schedules. Ann Oncol 2014; 25: 1-41.
46. Robert C, Joshua AM, Weber JS, et al. Pembrolizumab (MK-3475) for advanced melanoma: randomized comparison of two dosing schedules. Poster presented at: European Society for Medical Oncology 2014 Congress, 26-30 September 2014; Madrid, Spain.
47. Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016; 315: 1600-1609.
48. Garon E, Balmanoukian A, Hamid O, et al. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). Presented at: IASLC15th World Conference on Lung Cancer, 27-30 October 2013, Sydney, Australia.
49. Garon EB, Leighl NA, Rizvi NA, Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). Poster presented at the ASCO Annual Meeting, 30May- June 2014; Chicago, IL, USA.
50. Rizvi NA, Garon EB, Leighl N, et al. Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001. Poster presented at the ASCO Annual Meeting, 25 May-3 June 2015, Chicago, IL, USA.
51. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028.
52. Sul J, Blumenthal GM, Jiang X, et al. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 2016; 21: 643-650.
53. Corr P, Williams DE, The Pathway from idea to regulatory approval: examples for drug development. In B Lo, MJ Field (eds), Conflict of Interest in Medical Research, Education and Practice. Washington, DC: National Academies Press 2009.
54. Independent Institute. The drug development and approval process. FDAReview.org website. http://www.fdareview.org/03_drug_develop ment.php (28 February 2017, date last accessed).
55. Prowell TM, Theoret MR, Pazdur R. Seamless oncology-drug development. N Engl J Med 2016; 374: 2001-2003.
56. FDA approves expanded indication for Merck's Keytruda (pembrolizumab) for the treatment of patients with advanced melanoma [press release]. 12-18-2015. http://www.businesswire.com/news/home/20151218005982/en (28 February 2017, date last accessed).
57. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908-918.
58. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532.
59. Daud A, Ribas A, Robert C, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 2015; 33(suppl 15): Abstr 9005.
60. Robert C, Ribas A, Hamid O, et al. Three year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE001. Presented at 2016 ASCO AnnualMeeting, June 3-7, Chicago, IL.
61. FDA approves Merck's Keytruda (pembrolizumab) for patients with recurrent ormetastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy [press release]. 8-5-2016. http://www.businesswire.com/news/home/2016080500 5807/en (28 February 2017, date last accessed).
62. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17: 956-965.
63. Keytruda [package insert]. Whitehouse Station, NJ, USA: Merck, Sharp & Dohme Corp.; August 2016.
64. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-1550.
65. Keytruda [package insert]. Whitehouse Station, NJ, USA; Merck, Sharp & Dohme Corp.; October 2016.
66. Agilent Technologies. Agilent Technologies receives expanded FDA approval for use of Dako PDL1 IHC 22C3 pharmDx companion diagnostic in nonsmall cell lung cancer [press release]. 10-24-2016. http://www.agi lent.com/about/newsroom/presrel/2016/24oct-ca16033.html (15May 2017, date last accessed).
67. FDA approves Merck's Keytruda (pembrolizumab) for adult and pediatric patients with classical hodgkin lymphoma (cHL) refractory to treatment, or who have relapsed after three or more prior lines of therapy. [press release] 3-14-2017. http://investors.merck.com/news/press-releasedetails/2017/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-for- Adult-and-Pediatric-Patients-with-Classical-Hodgkin-Lymphoma-cHLRefractory- to-Treatment-or-Who-Have-Relapsed-After-Three-or-More- Prior-Lines-of-Therapy/default.aspx (16May 2017, date last accessed).
68. FDA approves Merck's Keytruda (pembrolizumab) as first-line combination therapy with pemetrexed and carboplatin for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. [press release] 5-10-2017. http://www.mercknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-keytrudapembrolizumab- first-line-combin (16May 2017, date last accessed).
69. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 2016; 34: 3733-3739.
70. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015; 125: 3393-3400.
71. Moskowitz CH, Ribrag V, Michot JM, et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). 56th Annual Meeting of the American Society of Hematology. Blood 2014; 124: 290.
72. Nanda R, Chow LQ, Dees EC, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Presented at: 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, 9-13 December 2014, San Antonio, TX.
73. O'Donnell PH, Plimack ER, Bellmunt J, et al. Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: results of a phase IB study. J Clin Oncol 2015; 33(suppl 7): Abstr 296.
74. Muro K, Bang YJ, Shankaran V, et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J Clin Oncol 2015; 33(suppl 3): Abstr 03.
75. New Keytruda (pembrolizumab) data at 2016 ASCO annual meeting includes three-year overall survival data in melanoma and updated overall survival data in non-small cell lung cancer as well as updated findings in head and neck cancer [press release]. 5-16-2016. http://www.business wire.com/news/home/20160516005363/en (28 February 2017, date last accessed).
76. Merck receives breakthrough therapy designation from US Food and Drug Administration for Keytruda (pembrolizumab) in advanced colorectal cancer [press release]. 11-2-2015. http://www.businesswire. com/news/home/20151102005577/en/(28 February 2017, date last accessed).
77. Merck receives breakthrough therapy designation from US food and drug administration for Keytruda (pembrolizumab) in classical Hodgkin lymphoma (cHL) [press release]. 4-18-2016. http://www.busi nesswire.com/news/home/20160418005495/en/(28 February 2017, date last accessed).
78. FDA grants priority review to Merck's supplemental biologics license application (sBLA) seeking approval for Keytruda (pembrolizumab) for new indication in microsatellite instability-high cancer [press release]. 11-28-2016. http://investors.merck.com/news/press-release-details/2016/FDA-Grants-Priority-Review-to-Mercks-Supplemental-Biologics- License-Application-sBLA-Seeking-Approval-for-KEYTRUDA-pembroli zumab-for-New-Indication-in-Microsatellite-Instability-High-Cancer/default.aspx (28 February 2017, date last accessed).